SciSparc Ltd. has made an important amendment to its recent filing with the Securities and Exchange Commission (SEC). The company corrected a typographical error in a convertible promissory note, which is crucial for maintaining accurate financial records and compliance with regulatory standards.

The amendment, filed on November 9, 2026, updates the floor price of the convertible promissory note from $0.11592 to the corrected amount of $0.11952. This adjustment is part of the company's ongoing efforts to ensure transparency and accuracy in its financial disclosures.

Background

SciSparc Ltd., which operates under the SIC code 2834 for Pharmaceutical Preparations, is publicly traded on the Nasdaq under the ticker SPRC. The company is focused on the development of innovative therapies and has been active in the capital markets to support its growth initiatives. Recent filings include a series of reports leading up to this amendment, with the original filing dated November 3, 2026.

What the Filing Says

The filing states, "This Amendment does not amend, modify or update any disclosures contained in the Original 6-K, except as specifically described in this Explanatory Note." This indicates that the correction is limited to the floor price and does not affect other aspects of the securities purchase agreement.

Impact

This amendment may impact investors and stakeholders by ensuring clarity in the terms of the convertible promissory note. Accurate financial reporting is critical for maintaining investor confidence and compliance with SEC regulations. Other companies in the pharmaceutical preparations sector may also be prompted to review their own financial instruments for similar discrepancies.

What's Next

The filing does not say what happens next regarding the securities purchase agreement or any further actions by the company.